ライフサイエンスコーパス: sequestrant

1 hibited by pertussis toxin, and a Gbetagamma sequestrant.

2 rboxyl terminus of GRK2, a known G betagamma sequestrant.

3 serve as a generalized lipid-mediated toxin sequestrant.

4 ts with pruritus not responding to bile salt sequestrants.

5 ted by heterologous expression of Gbetagamma sequestrants.

6 Data from 5 diet, 3 bile acid sequestrant, 1 surgery, and 10 statin trials, with 81,85

7 2/3 inhibition by expression of a Gbetagamma sequestrant, a GRK2/3 dominant-negative mutant, or siRNA

8 Furthermore, expression of the Gbetagamma sequestrant, alpha-transducin, inhibits both Ras activat

9 hat it may show efficacy as an in vivo venom sequestrant and may serve as a generalized lipid-mediate

10 Dose-response relations for bile acid sequestrants and statins are nonlinear, and most of thei

11 d proteins, a PEG-aptamer and oral polymeric sequestrants), and the first follow-on (generic products

12 owering therapy (niacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare benefici

13 dose-response relation of statins, bile acid sequestrants, and niacin and their additive LDL choleste

14 als for the single trials of diet, bile acid sequestrants, and surgery also included the 1:1 relation

15 th added niacin, ezetimibe, and/or bile acid sequestrants, and to understand the implications of thes

16 main therapeutic uses of polymeric drugs as sequestrants, antimicrobials, antivirals, and anticancer

17 Niacin and bile acid sequestrants appear to exert beneficial effects on ather

18 Statins and bile-acid sequestrants are effective LDL-lowering therapies for ma

19 Bile acid sequestrants are synthetic polymers that bind bile acids

20 BA sequestrants (BAS) complex bile acids in the intestinal

21 Bile acid sequestrants (BAS) lower plasma low density lipoprotein

22 Bile acid sequestrants (BAS) reduce LDL-C, yet their clinical effi

23 is toxin, decreased by PP1 and the betagamma-sequestrant, but unaffected by PD 98059.

24 Developing a sequestrant capable of broad-spectrum neutralization acr

25 atment reversed the effects of the bile acid sequestrant cholestyramine on Fgf15, Shp, and Cyp7a1 exp

26 rug Administration approval of the bile acid sequestrant colesevelam HCl for reducing glycemia in pat

27 patients with cholestasis with the bile salt sequestrant, colesevelam, but not placebo, effectively r

28 ministration of a TRPA1 antagonist or the BA sequestrant colestipol, which lowered circulating levels

29 Low-intensity statin plus bile acid sequestrant decreased LDL cholesterol level 0% to 14% mo

30 Here, we report how polymeric 'bacteria sequestrants', designed to bind to bacteria through elec

31 e use increased from 4.2% to 5.0%, bile acid sequestrants did not change significantly, and niacin us

32 Heterologous expression of Gbetagamma sequestrants (GRK2CT-GFP or Galpha(i)G203A), as well as

33 LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe) (between-grou

34 ble to favor the use of niacin and bile acid sequestrants in combination with statins, based on safet

35 Moreover, the use of niacin and bile acid sequestrants is supported by clinical outcome results fr

36 445) trials, and 1 trial each of a bile acid sequestrant (n = 3,806), diet (n = 458), and ileal bypas

37 acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consi

38 wer-intensity statin combined with bile acid sequestrant or ezetimibe among high-risk patients intole

39 If bile acid sequestrants or niacin are added to statin therapy, the

40 olesterol-lowering agent (statins, bile acid sequestrants, or niacin, at two or more doses) or 2) mon

41 coexpression of a Gbetagamma subunit complex sequestrant peptide (betaARK1ct) and dominant-negative m

42 Ca2+/calmodulin (CAM) inhibitors or the CAM sequestrant protein calspermin.

43 The atRAL sequestrant QEA-B-001-NH2 conferred protection against p

44 fter lipid-lowering treatment (statins, bile sequestrant resins).

45 y modification is causal because a bile acid sequestrant suppresses the beneficial effects of bile di

46 geted therapeutic approach using a bile acid sequestrant to improve both cholesterol and glucose mana

47 inhibited by overexpression of the betagamma-sequestrant, transducin.

48 n-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants onl

49 t clinical trials demonstrate that bile acid sequestrants, which significantly reduce LDL-C, can also